Related Experiment Videos
[Prognosis of primary cutaneous lymphomas]
1Service de Dermatologie, Hôpital Pasteur, 68024 Colmar Cedex, France. florent.grange@ch-colmar.rss.fr
Annales De Dermatologie Et De Venereologie
|April 9, 2002
Summary
Prognostic factors for primary cutaneous lymphomas help predict patient survival and guide treatment. Identifying these factors improves management and therapeutic strategies for these rare skin cancers.
Area of Science:
- Dermatology
- Oncology
- Hematology
Context:
- Prognosis assessment is crucial for managing primary cutaneous lymphomas (PCLs).
- Accurate prognostic information guides patient counseling and treatment decisions.
- Understanding survival outcomes is key to effective PCL management.
Purpose:
- To review global prognosis and prognostic factors in primary cutaneous lymphomas.
- To emphasize independent prognostic factors identified through multivariate survival analyses.
- To provide an overview of survival rates for various PCL subtypes.
Summary:
- Prognosis for mycosis fungoides has improved, with survival rates varying by stage (T1-T4).
- Lymphomatoid papulosis and CD30+ PCLs have excellent prognoses, while CD30-negative PCLs are aggressive.
- Prognosis for B-cell lymphomas varies, with immunocytomas and marginal-zone lymphomas being indolent, and leg-type large B-cell lymphomas having a poorer outlook.
Impact:
- Identified prognostic factors reliably predict survival outcomes in PCLs.
- Established prognostic data inform therapeutic guidelines and clinical trial design.
- This knowledge aids in evaluating novel prognostic markers for PCLs.